¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"B cell study"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
longitudinal study
ÃßÀû¿¬±¸
molecular genetic study
ºÐÀÚÀ¯ÀüÇа˻ç
neurophysiological study
½Å°æ»ý¸®ÇÐÀû°Ë»ç
observational study
°üÂû¿¬±¸
pilot study
¿¹ºñ¿¬±¸
population study
Àα¸Á¶»ç
preclinical study
ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
pressure flow study
¾Ð·Â¿ä·ù°Ë»ç
prospective cohort study
ÀüÇâÄÚȣƮ¿¬±¸
prospective study
ÀüÇ⿬±¸, °èȹ¿¬±¸
real time study
½Ç½Ã°£°Ë»ç
retrospective cohort study
ÈÄÇâÄÚȣƮ¿¬±¸
retrospective study
ÈÄÇ⿬±¸
study
1. ¿¬±¸, Á¶»ç 2. °Ë»ç, °Ë»ö
study design
¿¬±¸¼³°è
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
single blinding study
´Ü¼ø¸Í°Ë¹ý
urodynamic study
¿ä¿ªµ¿Çа˻ç
sickle cell anemia
³´ÀûÇ÷±¸ºóÇ÷
cell
¼¼Æ÷
accessory cell
º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
acinar cell
»ù²Ê¸®¼¼Æ÷
amacrine cell
¹«Ãà»è¼¼Æ÷
balloon cell
dz¼±¼¼Æ÷
basal cell
¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
basal cell carcinoma
¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
basket cell
¹Ù±¸´Ï¼¼Æ÷
basophilic cell
È£¿°±â¼¼Æ÷
beta cell
º£Å¸¼¼Æ÷
bipolar cell
µÎ±Ø¼¼Æ÷
blood cell
Ç÷¾×¼¼Æ÷, Ç÷±¸
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
feasibility study
°¡´É¼º¿¬±¸
first pass study
ÀÏÂ÷Åë°ú°Ë»ç
follow-up study
ÃßÀûÁ¶»ç
infection control study
°¨¿°°ü¸®Á¶»ç
intervening study
°³ÀÔ¿¬±¸
longitudinal study
ÃßÀû¿¬±¸
microbiologic study
¹Ì»ý¹°Çа˻ç
migrant study
ÀÌÁֹבּ¸
mixing study
È¥ÇÕ°Ë»ç
molecular genetic study
ºÐÀÚÀ¯ÀüÇа˻ç
neurophysiological study
½Å°æ»ý¸®ÇÐÀû°Ë»ç
nonconcurrent study
ºñµ¿½ÃÀû¿¬±¸
observational study
°üÂû¿¬±¸
pilot study
¿¹ºñ½ÇÇè
population study
Àα¸Á¶»ç
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
B cell
B¼¼Æ÷(~ á¬øà)
B cell
B ¼¼Æ÷
B cell
B ¼¼Æ÷.
B cell antigen
B ¼¼Æ÷Ç׿ø
B cell differentiation factor (BCDF)
B¼¼Æ÷ ºÐÈÀ¯¹ßÀÎÀÚ
B cell growth factor
B ¼¼Æ÷¼ºÀåÀÎÀÚ
B cell growth factor (BCGF)
B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
B cell hybridoma
B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
B cell lymphoma
B¼¼Æ÷¸²ÇÁÁ¾
B cell stimulating factor (BSF)
B¼¼Æ÷ ÀÚ±ØÀÎÀÚ
B cell/lymphocyte
B ¼¼Æ÷/¸²ÇÁ±¸
B-cell
ºñ ¼¼Æ÷
C-cell
C ¼¼Æ÷
CD4+ cell
CD4+ ¼¼Æ÷
Cell adhesion molecules
¼¼Æ÷À¯ÂøºÐÀÚ
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
nested case control study
phase 1 study
ÀÓ»óÁ¦1»ó½ÃÇè.
pilot study
¿¹ºñ½ÇÇè.
population study
Àα¸Á¶»ç
preclinical study
ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
pressure flow study
¾Ð·ù·® Á¶»ç
pressure-perfusion study
¾Ð·Â°ü·ù°Ë»ç
prospective study
°èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
real time study
½Ç½Ã°£ °Ë»ç
retrospective study
ÈÄÇâÀû¿¬±¸
single blind study
´ÜÀÏ<¼ø>¸Í°Ë¹ý.
time study
½Ã°£¿¬±¸(¡æÚϼ).
tracer study
ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
twin study
½Ö»ý¾Æ¿¬±¸(¡æÚϼ).
twin study
½Ö»ý¾Æ¿¬?¡æÚϼ)
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½